ClinicalTrials.Veeva

Menu

A Study Evaluating the Pharmacokinetics of Doravirine (MK-1439) in Participants With Severe Renal Impairment (MK-1439-051)

Merck Sharp & Dohme (MSD) logo

Merck Sharp & Dohme (MSD)

Status and phase

Completed
Phase 1

Conditions

Renal Impairment

Treatments

Drug: Doravirine

Study type

Interventional

Funder types

Industry

Identifiers

NCT02641067
MK-1439-051 (Other Identifier)
1439-051

Details and patient eligibility

About

This study will evaluate the effect of severe renal impairment on the pharmacokinetics of doravirine.

Enrollment

16 patients

Sex

All

Ages

18 to 75 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • is a non-smoker or moderate smoker
  • has a body mass index (BMI) ≥ 18.5 and ≤ 40.0 kg/m^2
  • other than renal impairment, participant is judged to be in good health based on medical history, physical examination, vital signs, and laboratory safety tests
  • female informed of the risks of pregnancy, agree not to become pregnant while participating in this study. Female of childbearing potential must either be sexually inactive for 14 days prior to dosing and throughout the study, or uses one acceptable birth control method
  • female of non-childbearing potential must have undergone sterilization procedures at least 6 months prior to dosing.
  • Participants with severe renal impairment only: has baseline estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73m^2

Exclusion criteria

  • is mentally or legally incapacitated or has significant emotional problems
  • has a history or presence of clinically significant medical or psychiatric condition or disease
  • has history or presence of alcoholism or drug abuse within the past 2 years
  • has history or presence of hypersensitivity or idiosyncratic reaction to the study drug, any inactive ingredients, or related compounds
  • has history or presence of renal artery stenosis
  • has had a renal transplant or nephrectomy
  • has rapidly fluctuating renal function as determined by historical measurements
  • female is pregnant or lactating
  • has positive results for the urine or saliva drug and urine or breath alcohol screen at screening or check-in
  • has positive results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV)
  • is unable to refrain from or anticipates the use of any drug, including prescription and non-prescription medications, herbal remedies, or vitamin supplements beginning 14 days prior to dosing and throughout the study. Certain medications including those to treat kidney disease will be permitted. Other medications may be permitted following consultation with the Sponsor Clinical Monitor.
  • is unable to refrain from or anticipates the use of inducers of cytochrome P450 3A (CYP3A) or permeability glycoprotein (P-gp) transporters for at least 28 days prior to dosing and throughout the study.
  • has been on a diet incompatible with the on-study diet, within 28 days prior to dosing, and throughout the study
  • has donated blood or had significant blood loss within 56 days prior to dosing
  • has donated plasma within 7 days prior to dosing
  • has participated in another clinical trial within 28 days prior to dosing

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

16 participants in 2 patient groups

Severe Renal Impairment
Experimental group
Description:
Participants with severe renal impairment receive a single oral dose of 100 mg doravirine
Treatment:
Drug: Doravirine
Healthy Matched Control
Experimental group
Description:
Healthy participants matched for age and weight receive a single oral dose of 100 mg doravirine
Treatment:
Drug: Doravirine

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems